Lurasidone monotherapy for the treatment of bipolar I depression: results of a 6-week, double-blind, placebo-controlled study

被引：0
|
作者：
Loebel, A. [1 ]
Cucchiaro, J. [1 ]
Silva, R. [1 ]
Sarma, K. [1 ]
Kroger, H. [1 ]
Calabrese, J. R. [2 ]
Sachs, G. [3 ,4 ]
机构：
[1] Sunovion Pharmaceut Inc, Ft Lee, NJ USA
[2] Univ Hosp Case Med Ctr, Cleveland, OH USA
[3] Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA
来源：
BIPOLAR DISORDERS | 2013年 / 15卷
关键词：
bipolar disorder; depression; atypical antipsychotics; randomized clinical trial;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [1] Lurasidone adjunctive to lithium or valproate for the treatment of bipolar I depression: results of a 6-week, double-blind, placebo-controlled study
    Loebel, A.
    Cucchiaro, J.
    Silva, R.
    Hsu, J.
    Sarma, K.
    Sachs, G.
    Calabrese, J. R.
    BIPOLAR DISORDERS, 2013, 15 : 137 - 138
  • [2] Double-blind,placebo-controlledstudy of lurasidone monotherapy for the treatment of bipolar I depression
    Kato, Tadafumi
    Ishigooka, Jun
    Miyajima, Mari
    Watabe, Kei
    Fujimori, Tomohiro
    Masuda, Takahiro
    Higuchi, Teruhiko
    Vieta, Eduard
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2020, 74 (12) : 635 - 644
  • [3] Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
    Masaaki Ogasa
    Tatsuya Kimura
    Mitsutaka Nakamura
    John Guarino
    Psychopharmacology, 2013, 225 : 519 - 530
  • [4] Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
    Ogasa, Masaaki
    Kimura, Tatsuya
    Nakamura, Mitsutaka
    Guarino, John
    PSYCHOPHARMACOLOGY, 2013, 225 (03) : 519 - 530
  • [5] Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial
    Higuchi, Teruhiko
    Iyo, Masaomi
    Kwon, Jun Soo
    Chou, Yuan-Hwa
    Chen, Hsing-Kang
    Chen, Jen-Yeu
    Chen, Tzu-Ting
    Huang, San-Yuan
    Lee, Jung-Sik
    Saeki, Yuichi
    Tanaka, Hisashi
    Wang, Tzong-Shi
    Wu, Bo-Jian
    Katoh, Takao
    Ishigouoka, Jun
    ASIA-PACIFIC PSYCHIATRY, 2019, 11 (03)
  • [6] Lurasidone Adjunctive Therapy with Lithium or Valproate for the Treatment of Bipolar I Depression: A Randomized, Double-blind, Placebo-controlled Study (PREVAIL 3)
    Suppes, Trisha
    Calabrese, Joseph R.
    Silva, Robert
    Kroger, Hans
    Cucchiaro, Josephine
    Pikalov, Andrei
    Loebel, Antony
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S533 - S534
  • [7] Efficacy and safety of lurasidone in schizophrenia: pooled analysis of European results from double-blind, placebo-controlled 6-week studies
    Calisti, Fabrizio
    Cattaneo, Agnese
    Calabrese, Mariangela
    Mao, Yongcai
    Tocco, Michael
    Pikalov, Andrei
    Goldman, Robert
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2022, 37 (05) : 215 - 222
  • [8] Quetiapine in bipolar I depression: double-blind, placebo-controlled study
    Macfadden, W
    Calabrese, JR
    Suppes, T
    McCoy, R
    Minkwitz, M
    Wilson, E
    Mullen, J
    BIPOLAR DISORDERS, 2005, 7 : 72 - 73
  • [9] Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials
    Calabrese, Joseph R.
    Huffman, Russell F.
    White, Robin L.
    Edwards, Suzanne
    Thompson, Thomas R.
    Ascher, John A.
    Monaghan, Eileen T.
    Leadbetter, Robert A.
    BIPOLAR DISORDERS, 2008, 10 (02) : 323 - 333
  • [10] A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life
    Endicott, Jean
    Rajagopalan, Krithika
    Minkwitz, Margaret
    Macfadden, Wayne
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (01) : 29 - 37
12345